News
The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...
Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...
1d
Zacks Investment Research on MSNEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.
Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...
Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...
With Richard Ayoade with David Letterman, Robert Downey Jr., Kamilah Forbes, Scott Galloway, Tom Hanks, Becky Kennedy, and ...
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results